An Exploratory Phase 2 Study to Determine Safety, Tolerability and Impact of BGP-15 on cardiac fibrosis and ventricular remodelling in patients with Non-Ischaemic Dilated Cardiomyopathy (NIDCM)
Latest Information Update: 29 Nov 2019
At a glance
- Drugs BGP 15 (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions
- Sponsors N-Gene Research Laboratories
- 28 Nov 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 18 Jun 2016 New trial record